Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.72 |
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.63 |
| ▸ | RELA | Q04206 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26145311 | 1.00 | KDM4E (1.00) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| SCHEMBL2072196 | 0.94 | KDM4E (0.89) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| SCHEMBL26145349 | 0.92 | KDM4E (0.84) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| SCHEMBL26145337 | 0.88 | RAB9A (0.82) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| SCHEMBL26145333 | 0.88 | SMN1; SMN2 (0.78) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| SCHEMBL26145327 | 0.85 | KDM4E (0.74) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| SCHEMBL26145323 | 0.85 | CYP3A4 (0.74) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| SCHEMBL26145325 | 0.85 | KDM4E (0.74) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| SCHEMBL7564891 | 0.85 | SMN1; SMN2 (0.73) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 | |
| Biochanin A, Dimethyl Ether SCHEMBL5795557 | 0.84 | CYP3A4 (1.00) | KDM4ESMN1; SMN2CYP3A4HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478605-B2 | Biochanin a derivatives for treatment of BEST1-related retinopathies | UNIVERSITÄT REGENSBURG (DE) | 2025-11-25 | — | — | US | claimed |
| EP-4125866-B1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | UNIV REGENSBURG (DE) | 2025-10-08 | — | — | EP | claimed |
| CN-115335045-B | Modulators of mutation bestrophin for the treatment of BEST 1-related retinopathy | 雷根斯堡大学 | 2025-03-18 | — | — | CN | claimed |
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | UNIVERSITÄT REGENSBURG (AT) | 2023-05-18 | — | — | US | claimed |
| EP-4125866-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1 -RELATED RETINOPATHIES | Universität Regensburg (DE) | 2023-02-08 | — | — | EP | claimed |
| CN-115335045-A | Mutant bestrophin 1 modulators for the treatment of BEST 1-related retinopathy | 雷根斯堡大学 | 2022-11-11 | — | — | CN | claimed |
| US-12478605-B2 | Biochanin a derivatives for treatment of BEST1-related retinopathies | UNIVERSITÄT REGENSBURG (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4125866-B1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | UNIV REGENSBURG (DE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250207095-A1 | MANUFACTURING PROCESSES FOR ADOPTIVE CELL THERAPIES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-06-26 | — | — | US | disclosed |
| EP-4562131-A2 | MANUFACTURING PROCESSES FOR ADOPTIVE CELL THERAPIES | Memorial Sloan Kettering Cancer Center (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-115335045-B | Modulators of mutation bestrophin for the treatment of BEST 1-related retinopathy | 雷根斯堡大学 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024025878-A2 | MANUFACTURING PROCESSES FOR ADOPTIVE CELL THERAPIES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | UNIVERSITÄT REGENSBURG (AT) | 2023-05-18 | — | — | US | disclosed |
| EP-4125866-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1 -RELATED RETINOPATHIES | Universität Regensburg (DE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335045-A | Mutant bestrophin 1 modulators for the treatment of BEST 1-related retinopathy | 雷根斯堡大学 | 2022-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | SORBS1, SLC5A6, SLC20A1 | KDM4E 2594/4885SMN1; SMN2 252/4885CYP3A4 4678/4885 |
| US-12478605-B2 | Biochanin a derivatives for treatment of BEST1-related retinopathies | SORBS1, SLC5A6, SLC20A1 | KDM4E 2594/4885SMN1; SMN2 252/4885CYP3A4 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.